wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q57135350
Q57135350
Item
http://www.wikidata.org/entity/Q57135350
Q57135350
about
Q57135350
Item
http://www.wikidata.org/entity/Q57135350
description
wetenschappelijk artikel
@nl
наукова стаття, опублікована в січні 2012
@uk
type
Item
P1433
Q57135350-A5E294AB-9E42-4845-B359-02AE41CFCB3F
P2093
Q57135350-59F65A19-2CB7-4F4E-8A11-9AD79C9D45FE
Q57135350-6A9C1F86-CB76-43B0-9277-55756F8EFA87
P2860
Q57135350-0A4D6CB7-6DBE-4656-925A-D055132B1E2B
Q57135350-0AD60E92-BED7-442A-A12C-A3C75C264100
Q57135350-15FCDCFE-FA30-48B7-9441-1AB763049260
Q57135350-291B84C7-3D7D-40D2-934F-93BED9947494
Q57135350-2FCA7164-EA4F-4579-AC33-5AAC0DFE3FBE
Q57135350-3793F613-5731-4BB5-93B5-B4FF80A3B714
Q57135350-479E12A5-0A23-4629-BE77-D30E43DA9438
Q57135350-62444D79-CD89-4616-9DD2-CE816FEAA090
Q57135350-69F10958-C922-403F-8295-57779BB90CE2
Q57135350-75C0B36E-C898-4B00-B7AA-53D56300FA2E
Show more
P304
Q57135350-A3DF47D2-09EF-4C83-824D-87986E75FFA7
P31
Q57135350-BEB15BA4-6683-4CF3-9B75-2AFDD2A11360
P356
Q57135350-0A9831FC-67AC-498D-B9DF-78F706585423
P433
Q57135350-2474F973-163F-4C8F-89D5-CF258BA6AE6E
P478
Q57135350-B6D1467A-36D0-4A87-AF91-9F9438E6512C
P577
Q57135350-E29420B1-8DEE-4D6A-BB1A-D66121115F93
P698
Q57135350-A4CD2972-6CE3-4751-8F27-7D2779211EB7
P356
S00120-011-2739-8
P1433
Der Urologe. Ausg. A
P2093
M Bachner
http://www.w3.org/2001/XMLSchema#string
M De Santis
http://www.w3.org/2001/XMLSchema#string
P2860
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
Abiraterone and increased survival in metastatic prostate cancer
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate.
Phase II study of low-dose docetaxel/estramustine in elderly patients or patients aged 18-74 years with hormone-refractory prostate cancer.
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer.
Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology.
The medical management of prostate cancer: a multidisciplinary team approach.
Chemotherapy for older patients with prostate cancer.
Show more
P304
39-43
http://www.w3.org/2001/XMLSchema#string
P31
scholarly article
P356
10.1007/S00120-011-2739-8
http://www.w3.org/2001/XMLSchema#string
P433
1
http://www.w3.org/2001/XMLSchema#string
P478
51
http://www.w3.org/2001/XMLSchema#string
P577
2012-01-01T00:00:00Z
http://www.w3.org/2001/XMLSchema#dateTime
P698
22258375
http://www.w3.org/2001/XMLSchema#string